← All trials
NCT04263090
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2020
- Primary completion
- Jan 31, 2022
- Completion date
- Jan 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiReponsible party - principal investigator
- Onconova Therapeutics, Inc.Collaborator
- Icahn School of Medicine at Mount SinaiSponsor investigator
- Bristol-Myers SquibbCollaborator
- Traws Pharma, Inc.Collaborator
- Icahn School of Medicine at Mount SinaiOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.